MKI67 and sarcoma: Standardized methods to assess TLS positivity need to be further specified, and positivity is currently entrusted to well-trained sarcoma pathologist experts; as previously reported with many other immunohistochemistry biomarkers such as Ki67, inter- and intra-observer variability cannot be excluded.